SLNO Q3 2017 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$3M

Operating Income

-$3M

Net Income

-$4M

EPS (Diluted)

$-5.87

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$227,000

Balance Sheet

Total Assets

$26M

Total Liabilities

$3M

Stockholders' Equity

$23M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$329,000	-100.0%
Gross Profit	-$3M	-$70,000	-3741.4%
Operating Income	-$3M	-$3M	+8.6%
Net Income	-$4M	-$3M	-37.7%